Cases & Deals

  • Home
  • Practices
  • Perlan establishes global patent portfolio for ICAM1 antibodies

Share

Perlan establishes global patent portfolio for ICAM1 antibodies

January 2015

Client(s) Perlan Therapeutics, Inc.

Jones Day represents Perlan Therapeutics, Inc. in connection with the global patent portfolio for ICAM1 antibodies for the treatment of rhinovirus and other respiratory infections.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.